G19 is a novel homogeneous sulfated oligosaccharide, prepared from Grateloupia filicina. In the present study, we first reported that oligosaccharide G19 exhibited a doseand time-dependent anti-proliferation effect against U-87 malignant gliomas (MG) human glioma cells. Further studies indicated that G19 strongly bound to epidermal growth factor (EGF), suppressed EGF receptor phosphorylation and interrupted the phosphatidylinositol-3 kinase/Akt pathway in the cancer cells. Moreover, G19 elevated intracellular reactive oxygen species levels and caused endogenous DNA damage. These actions were associated with activation of ataxia-telangiectasia-mutated/checkpoint kinase 2 pathway. The downregulation of MDM2 with stabilizing p53 and the nuclear location of p21 were induced by G19 to cause cell cycle arrest and apoptosis to some extent. Meanwhile, intrinsic mitochondrial pathway and extrinsic death receptor pathway were involved in G19-mediated apoptosis. Pretreatment with free radical scavenger N-acetyl-L-cysteine nearly completely inversed G19-induced cell growth inhibition, cell cycle arrest and apoptosis in U-87 MG cells. Importantly, G19 could inhibit the growth of U-87 MG tumor cells xenograft in nude mice. The results suggested that G19 could be served as a new targeting drug candidate for human glioma treatment.
Introduction
Human glioma is the most frequent and lethal cancer of brain tumors in adults central nervous system (Furnari et al. 2007 ). According to the histopathological features and clinical presentation, primary brain tumors can be graded from I to IV, with grade I and II as astrocytomas derived from star-shaped astrocyte-like cells, grade III as anaplastic astrocytomas and grade IV as multiform glioblastomas. Although the rate of glioma is about 10-fold lower compared with lung and breast cancer, glioma has serious effects on the health-care system in general, and especially on patients and their families (Frosina 2009 ). Despite decades of research efforts, human glioma patients remain refractory to current treatment modalities including surgery, ionizing radiation and DNA-alkylating agents temozolomide (TMZ) and have a poor prognosis (Becker and Yu 2012) . Other than surgery, the most prevalent cancer treatments are radiotherapy and chemotherapies that function by generating DNA damage. The dismal prognosis of glioma is mainly due to the diffuse infiltrative nature of this disease and a number of resistance mechanisms among which DNA repair may play a role. Several genetic alterations commonly found in glioma (such as epidermal growth factor receptor (EGFR) amplification and phosphatase and tensin homolog (PTEN) inactivation) could directly be responsible for the therapy resistance of this tumor type. Recent researches indicate that EGFR modulates DNA double-strand break (DSB) repair by regulating nonhomologous end-joining, hyperactivating phosphatidylinositol-3 kinase (PI3K)/Akt signaling and EGFR nuclear translocation (Mukherjee et al. 2009; Kriegs et al. 2010; Liccardi et al. 2011) . Therefore, combined treatment with EGFR inhibitor and DNA-damaging agent may represent an effective therapeutic strategy for glioma. Previously, acidic polysaccharides have been reported to exhibit a dose-dependent anti-proliferative effect against human breast cancer michigan cancer foundation-7 cells with the observation of intracellular reactive oxygen species (ROS) production and DNA damage (He et al. 2012) . This inspired us to discover novel acid polysaccharides/oligosaccharides with DNA damage property in glioma treatment.
Grateloupia filiciina is a red marine algae belonging to the Halymeniaceae family. Grateloupia filicina polysaccharide (GFP) is demonstrated to be one of the major active ingredients from G. filicina, since after optimization of the extraction conditions, yield of the polysaccharides from the dried algae could be 47% (Zhu et al. 2006) . Recent studies indicate that GFP possesses diverse bioactivities including anti-human immunodeficiency virus-1 (Wang et al. 2007) , antioxidant (Zhu et al. 2008) , anticoagulation (Athukorala et al. 2008 ) and anti-angiogenesis . Theoretically, as a drug candidate, quality control of oligosaccharide with small molecular weight is easier than that of polysaccharide (Li et al. 2013) . However, to our knowledge, there is no paper published in which mentioned the bioactivity of oligosaccharide isolated from G. filicina and little is known about its effect on cancer cells.
To address this, G19, one homogeneous sulfated oligosaccharide with molecular weight of 1722 Dalton, prepared from G. filicina, was studied. It was a sulfated β-D-galactan which composed of seven galactosyl residues. The sulfate group was substituted at O-4 of 1,3-linked galactosyl residue. In this study, we investigated the anti-tumor effect of oligosaccharide G19 on U-87 malignant gliomas (MG) human glioma cells in vitro and in vivo and the underlying molecular mechanism of this action.
Results

G19 inhibits U-87 MG cells growth
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed to investigate the potential effect of G19 on the viability of U-87 MG cells. Cells were incubated with different concentrations of G19 (0.01, 0.05, 0.1, 0.2 and 0.4 mg/mL) for 24, 48 and 72 h, respectively. The cell viability was determined by formazan dye uptake and expressed as percent compared with untreated cells. As shown in Figure 1A , G19 could inhibit U-87 MG cells growth in a dose-and timedependent manner. The IC 50 of G19 was at 0.176 mg/mL for 24 h, 0.069 mg/mL for 48 h and 0.047 mg/mL for 72 h, respectively. Meanwhile, it was found that G19 had minimal deleterious effects on hepatocytes (Supplementary data, Figure S1 ).
G19 causes U-87 MG cells cycle arrest
To gain further insight into the mechanism of the growth inhibitory effect of G19, cells were treated with 0.05 and 0.1 mg/mL of G19 for indicated times and analyzed using propidium iodide (PI) staining and flow cytometry. The distribution in different phases of cell cycle was illustrated in Table I . Representative pictures were shown in Figure 1B and C. The proportion of cells in G0-G1 phase was reduced during G19 treatment. The reduction was accompanied by an increase in the percentage of cells in S phase in a dose-dependent manner (Table I ). Interestingly, cell cycle was extensively arrested in G2-M phase after the cells were treated with 0.1 mg/mL G19 for 48 h ( Figure 2B and Table I ).
P21-cyclin A signaling is regulated by G19 in U-87 MG cells p21, a member of the Cip/Kip family of cyclin-dependent kinase inhibitors (CKIs), could interact with the CDK2-cyclin complex and inhibit the kinase activity, ultimately leading to cell cycle arrest (Sherr and Roberts 1995) . We speculated that the expression of p21 might be altered after G19 treatment. After cells were treated with 0.1 mg/mL G19 for 24 h, the expression of p21 was determined by reverse transcriptionpolymerase chain reaction (RT-PCR) and western blotting. As shown in Figure 1D and E, 0.1 mg/mL G19 increases the expression of p21 at mRNA and protein levels. The cell-growth-inhibiting activity of p21 is strongly correlated with its nuclear localization (Goubin and Ducommun 1995; Sherr and Roberts 1995) . After treatment with 0.1 mg/mL G19 for 24 h, p21 was significantly upregulated in the nucleus ( Figure 1F ). Thus, G19 rendered cell cycle arrest via promoting nuclear translocation of p21. Cyclin A is important in the vertebrate cell cycle for the onset of both DNA replication and mitosis (Chibazakura et al. 2011) . Cyclin A and CDK2 could regulate cell progression from late G1 to S phase and their activity is negatively regulated by p21. Figure 1E showed that the expression of cyclin A was clearly completely blocked, whereas the expression of CDK2 was not changed after G19 treatment.
In order to assess the role of p21 in response to G19 treatment on U-87 MG cells, we first measured the expression of p21 and cyclin A after ablation of p21 with siRNA. As shown in Figure 1G , the expression of p21 was almost completely disrupted by p21 siRNA whereas the expression of cyclin A was upregulated. Transfection of U-87 MG cells with p21 siRNA would abolish p21 increase induced by G19 ( Figure 1G ). Meanwhile, cells transfected with p21 siRNA failed to suppress the expression of cyclin A in response to G19 treatment ( Figure 1G ). These results indicated that suppression of cyclin A induced by G19 might be through p21 function. MTT assay demonstrated that the cell viability after p21 siRNA transfection was significantly increased compared with that of the sham transfection or the control cells for 24 h in response to G19 treatment ( Figure 1H ; P < 0.01). This suggested that cyclin A increase by depletion of p21 in the presence of G19 was implicated in cell viability. Furthermore, when the expression of cyclin A was enhanced by p21 siRNA transfection ( Figure 1G ), the percentage of cells in S-phase was increased ( Figure 1I ). This result was consistent with previous report that knockdown of p21 increased the number of cells distributed in S phase in prostate carcinoma cells (Roy et al. 2007 ). Intriguingly, cell cycle arrest caused by G19 was released after p21 was depleted by its siRNA transfection, since the percentage of the cells in S phase in this case was at the same levels as those of the untreated cells ( Figure 1I ). These results suggested that mild increase of cyclin A following p21 knockdown might be implicated in cell viability and cell cycle, while the regulation of the function of p21 might play an important role on cells growth inhibition and cell cycle arrest in response to G19 treatment in U-87 MG cells.
G19 elevates p21 expression via p53 activation in U-87 MG cells p53 binding to nucleosome within p21 promoter in vivo could lead to nucleosome loss and transcriptional activation (Laptenko et al. 2011) . The next question to be addressed was that whether p21 induced by G19 was linked to p53 function in U-87 MG cells. Surprisingly, the phosphorylations of p53 at Ser 15, Ser 20 and Ser 46 were all activated significantly, while total p53 expression was also upregulated after G19 treatment ( Figure 2A ). When cells were incubated with 0.1 mg/mL G19 alone or combined with 10 μM pifithrin-α (a transactivation blocker of p53), pifithrin-α could suppress the expression of p21 induced by G19 ( Figure 2B ). These data suggested that G19 activated p53 to upregulate p21 in U-87 MG cells. 
Downregulated MDM2 stabilizes p53 after G19 treatment
Although total p53 expression at protein level was increased (Figure 2A ), the expression of p53 at mRNA level was not altered upon G19 exposure ( Figure 2C ). It indicated that there might be a posttranscriptional regulation of p53 after G19 treatment. MDM2 targets p53 for proteasome-mediated protein degradation (Grossman et al. 1998) . As shown in Figure 2D , 0.1 mg/mL G19 obviously downregulated the expression of phospho-MDM2 (Ser 166) in U-87 MG cells. Thus, G19 might stabilize p53 though downregulating MDM2 in U-87 MG cells, similar to the effect of PI3K inhibitor LY294002 (Supplementary data, Figure S2 ).
G19 suppresses PI3K/Akt signaling in U-87 MG cells Cell growth inhibition induced by Akt signaling is correlated with nuclear localization of p21 . To address whether the nuclear localization of p21 induced by G19 was associated with Akt activation, the expressions of phosphoAkt (Ser 473) and Akt were detected by western blotting. The expression of phospho-Akt (Ser 473) was significantly downregulated in a dose-dependent manner, whereas Akt was not changed upon G19 treatment ( Figure 3A) . Thus, G19 could block Akt signaling activation in U-87 MG cells.
PI3K has emerged as an important constituent of many critical signaling pathways. Several biological effects of PI3K are mediated through activation of downstream target Akt. Because Akt signaling was blocked in U-87 MG cells after G19 treatment ( Figure 3A) , we wondered whether the downregulation of Akt phosphorylation was due to PI3K inactivation. PI3K could phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), then transformed nicotinamide adenine dinucleotide hydrogen (NADH) to NAD + through the system of pyruvate kinase (PK) and lactate dehydrogenase. The activity of PI3K in the cells could be measured based on the level of NADH by GENMED PI3K Assay Kit. G19 obviously inhibited PI3K activity in a dose-dependent manner compared with the control group ( Figure 3B ). G19 effectively suppressed Akt phosphorylation and upregulated p21 expression in U-87 MG cells, similar to the effect of PI3K inhibitor LY294002 (Supplementary data, Figure S2 ). Next, we asked whether G19 targeted PI3K to inhibit Akt activation. Although G19 could strongly bind to PI3K by quartz crystal microbalance (QCM) analysis (Supplementary data, Figure S3 ), it could not change the activity of PI3K at kinase level ( Figure 3C ). Meanwhile, the expressions of phospho-PI3K p85 (Tyr458)/p55 (Tyr199), PI3K P110α and PI3K p85 (19H8) were not disturbed by G19 (data not shown). Therefore, we speculated that G19 might suppress the upstream signal effectors of PI3K to block PI3K/Akt signaling pathway.
G19 downregulates the phosphorylation of EGFR Since PI3K could be activated by receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCRs) (Katso et al. 2001) , we tested whether G19 suppressed activation of the Figure 3D ). Since the increased EGFR signaling has been linked to glioblastomas (Furnari et al. 2007; Network. 2008) , we focussed on the phosphorylation of EGFR. The binding test between G19 and EGF was performed by QCM analysis. The G19-EGF interaction was tested by injecting EGF in running buffer onto the G19 biosensor surface, and the frequency response was displayed (upper curve). As a control, the frequency responses by the EGF interaction with the streptavidin surface were measured (lower curve). (G) The cells were incubated in 96-well plate for 24 h in the presence of EGF, G19 or both of them followed by MTT assay. (H) The cells were treated with 0.1 mg/mL G19 or/and 10 ng/mL EGF followed by Western blot analysis probed with anti-phospho-EGFR (Tyr 1068), anti-EGFR, anti-phospho-Akt (Ser 473) and anti-p21 antibody. The band densities of phospho-EGFR (Tyr 1068) normalized to total EGFR were shown on the top of panel. The band density of phospho-EGFR (Tyr 1068) normalized to total EGFR in the control group was considered as 1. All experiments were repeated thrice. (*P < 0.05; **P < 0.01; ***P < 0.001.)
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Activated EGFR can stimulate downstream signaling effectors that included PI3K, Akt, ras sarcoma (Ras) and mitogenactivated protein kinase (MAPK). Western blotting result further showed that phospho-EGFR (Tyr 1068) was downregulated in a time-dependent manner upon G19 treatment ( Figure 3E ). It was in accordance with the results obtained from Proteome Profiler™ Human Phospho-RTK Array Kit ( Figure 3D ).
G19 binds to EGF
G19 could inhibit EGFR phosphorylation and suppress PI3K/ Akt signaling, similar to the effect of EGFR inhibitor lapatinib (Supplementary data, Figure S4 ). Therefore, we examined whether G19 could target EGFR to block PI3K/Akt pathway. The binding test between G19 and EGFR was measured by QCM. However, there was no significant shift produced between control and G19 group (data not shown). It meant that G19 could not bind to EGFR. The ligands of EGFR included EGF and transforming growth factor α (TGF-α) (Bublil and Yarden 2007; Sergina and Moasser 2007) . We found that G19 could not bind to TGF-α (data not shown). As shown in Figure 3F , two curves of control and G19 group were huge difference by QCM analysis. The result indicated that G19 could strongly bind to EGF. EGF could activate EGFR to promote cell growth (Henson and Gibson 2006) . Indeed, EGF stimulated U-87 MG cells growth ( Figure 3G ). Meanwhile, when combined treatment with 10 ng/mL EGF and 0.1 mg/mL G19, cell viability was significantly increased compared with 0.1 mg/mL G19 treatment alone ( Figure 3G ). It meant that EGF could counteract the cell growth suppression caused by G19, to some extent. As shown in Figure 3H , EGF could also induce the phosphorylation of EGFR at Tyr 1068 in U-87 MG cells after G19 treatment. Although G19 could inhibit Akt phosphorylation, we did not know whether this inhibition was via interrupting EGF/p21 signaling pathway. To test, phospho-Akt (Ser 473) and p21 were detected when the cells were treated with G19 and/or EGF. Indeed, EGF could induce phospho-Akt (Ser 473) and inhibit the expression of p21 in U-87 MG cells after G19 treatment ( Figure 3H ). All of the above data suggested that G19 inhibited cell proliferation through binding to EGF directly and further blocked EGFR /PI3K/Akt signaling pathway in U-87 MG cells.
G19 triggers DNA damage in U-87 MG cells
Cell cycle arrest is initiated via activation of DNA damage response (Barzilai and Yamamoto 2004) . To evaluate DNAdamaging effect of G19, the phosphorylation of histone H2A.X at Ser 139, a marker for DNA damage (Pilch et al. 2003) , was detected by western blotting. G19 dramatically increased the phosphorylation of histone H2A.X in a time-dependent manner ( Figure 4A ). The result was confirmed by examination of phosphorylated histone H2A.X in situ with immunofluorescent staining ( Figure 4B ). As shown in Figure 4B , 0.1 mg/mL G19 induced the accumulation of phospho-H2A.X in nucleus. Comet assay is usually employed to detect a variety of DNA damage in individual cell, including single-strand breaks, DSB, alkalilabile sites, incomplete excision-repair sites and DNA crosslink (Collins 2004; Olive and Banath 2006) . After 0.05 and 0.1 mg/mL G19 treatment for 24 h, an obvious characteristic "comet" migration pattern of relaxed DNA was observed in U-87 MG cells ( Figure 4C ). However, only obscure "halos" without clear direction was found in control group ( Figure 4C ). Quantitative analysis of comet assay results with CometScore™ software showed that the tail moment of G19-treated cell increased significantly compared with control group ( Figure 4D ).
Ataxia-telangiectasia mutated/Checkpoint kinase 2 pathway plays a critical role on p53 activation after G19 treatment The phosphorylation of p53 on Ser 15 is one of the most frequently used "read-out" of ataxia-telangiectasia mutated (ATM) activity, and phosphorylations of p53 at Ser 20 and 46 are also dependent on the presence of ATM in response to DNA damage (Saito et al. 2002) . As shown in Figure 4E , ATM was robustly phosphorylated at Ser 1981 in a dose-dependent manner after G19 treatment. Ser 1981-phosphorylated ATM causes dimer dissociation and initiates cellular ATM kinase activity leading to phosphorylation of the downstream cellular targets p53 and checkpoint kinase 2 (Chk2) (Lee and Paull 2005) . Since Chk2 is a major transducer in signaling pathway mediated by ATM, we next analyzed the phosphorylation of Chk2 using specific antibody to gain further information of G19-induced ATM activity. The phosphorylation of Chk2 at Thr 68 was also upregulated upon G19 exposure ( Figure 4E ). Meanwhile, phosphorylation of Chk2 at Thr 68 was significantly blocked after ATM was knocked down by siRNA in U-87 MG cells (Supplementary data, Figure S5 ). These findings suggested that G19 activated ATM/Chk2 signaling to upregulate the expression of phosphorylated p53 in response to DNA damage in U-87 MG cells.
P53 plays critical roles in G19-mediated cell growth inhibition in U-87 MG cells G19 could activate ATM/Chk2 signaling and phosphorylate p53 in U-87 MG cells (Figure 2A and 4E) . Meanwhile, the increased p21 was associated with activated p53 after G19 treatment ( Figure 2B ). Next, we examined the effect of p53 on the cell viability of U-87 MG cells during G19 treatment. As shown in Figure 4F , the cell viability was significantly increased after co-incubation with 5 μM pifithrin-α and 0.1 mg/ mL G19 for 48 h compared with G19 group (P < 0.001).
G19 increases the levels of reactive oxygen species and hydrogen peroxide while decreases mitochondrial member potential The accumulation of intracellular ROS is mostly thought to be a generator of endogenous oxidative DNA damage (Barzilai and Yamamoto 2004) . Using 2′,7′-dichlorofluorescein diacetate (DCFH-DA)-based detection and fluorescence microscope, Figure 5A showed that 0.1 mg/mL G19 induced intracellular ROS generation in U-87 MG cells. The results of flow cytometry analysis demonstrated that the mean fluorescence intensity (MFI) produced by ROS in U-87 MG cells was dramatically increased in a time-and dose-dependent manner after G19 treatment ( Figure 5B -E). Meanwhile, hydrogen peroxide (H 2 O 2 ) levels in U-87 MG cells were also obviously increased in a time-dependent manner after 0.1 mg/mL G19 treatment ( Figure 5F ). Furthermore, mitochondrion is believed to be a major site of ROS production. We observed an obvious decrement of mitochondrial member potential (MMP) upon G19 exposure ( Figure 5G ). These results suggested that mitochondrion might be the main source of ROS during G19 treatment in U-87 MG cells. Next, we test that whether EGF was implicated in ROS generation in U-87 MG cells in response to G19 treatment. U-87 MG cells was treated with 0.1 mg/mL G19 for 30 min, followed by addition of 10 ng/mL EGF into medium and maintaining for 23.5 h. As shown in Figure 5H and I, EGF could partially reduce the ROS generation induced by G19 in U-87 MG cells. It indicated that ROS induced by G19 was implicated in EGFR inactivation in U-87 MG cells.
G19 induces apoptosis in U-87 MG cells
Apoptotic cell death is generally caused by anti-tumor drugs at elevated concentrations. An increment of Sub-G1 population was observed after cells are treated with 0.1 mg/mL G19 for 48 h ( Figure 1C ). To further determine whether apoptosis could be induced by higher dosage of G19 in U-87 MG cells, cells were treated with 0.1 and 0.2 mg/mL G19 for 24 or 48 h followed by 1 mg/mL G19 for 6 h and incubated with monoclonal phospho-histone H2A.X (Ser 139) antibody followed by incubation of anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 555 Conjugate) (red). Cell nucleus was stained with DAPI (blue). The typical phospho-histone H2A.X foci in cell nucleus ( pink) was found in the merged graph. Images were observed at ×200 magnification. Scale bar, 10 µm. (C) Comet assay was performed when cells were treated with different concentrations of G19 for 24 h. The image in the dotted line box of each graph is a magnification of representative nucleus. Images were observed and captured using fluorescence microscope at ×200 magnification. Scale bar, 10 µm. (D) Quantification analysis of the results presented in (C). The tail moment from three independent experiments was calculated using CometScore™ software. (E) The cells were treated with different concentrations of G19 for 6 h. Western blot analysis was employed to measure the phospho-ATM (Ser 1981) and phospho-Chk2 (Thr 68). (F) The cells were treated with 0.1 mg/mL G19 alone or combined with 5 μM pifithrin-α for 48 h, followed by cell viability assay using MTT test. Results are mean ± SD from three independent experiments. (***P < 0.001.)
H Liu et al. G19 inhibits U-87 MG human glioma cells growth in vitro and in vivo apoptosis assay using dual-staining with Alexa® Flour 488 Annexin V and PI ( Figure 6A ). The amount of apoptosis cells was increased significantly in a dose-dependent manner after G19 treatment ( Figure 6B and C). After G19 treatment for 48 h, the amount of apoptosis cells was gradually increased from 15.6 to 40.18%, which was significantly different from control group (7.52%) ( Figure 6C ) (P < 0.01). To understand the underlying mechanism, we first detected the expression of some genes involved in the intrinsic mitochondrial pathway and extrinsic death receptor pathway by RT-PCR. As shown in Figure 6D and E, the expressions of Bax, Apaf-1, caspase-9 and caspase-3 at mRNA level are increased while Bcl-2 was decreased after G19 treatment. In addition, the expressions of Fas, FasL and caspase-8 at mRNA level were also upregulated ( Figure 6F ). Western blot results showed that G19 could increase the expressions of cleavage of caspase-3, PARP, Bcl-2, cytochrome c in cytosol and FasL at protein level ( Figure 6G and H). Thus, G19 caused cell apoptosis via both intrinsic mitochondrial pathway and extrinsic death receptor pathway in U-87 MG cells.
G19-induced cell growth inhibition, cell cycle arrest and apoptosis are associated with intracellular ROS generation Pretreatment with the free radical scavenger N-acetyl-L-cysteine (NAC) (10 mM) markedly abrogated G19-induced ROS generation in U-87 MG cells ( Figure 7A and B). To determine whether ROS generation was involved in G19-induced cell growth inhibition, U-87 MG cell viability was assessed after treatment with 0.1 mg/mL G19 in the presence or absence of NAC. The results indicated that NAC completely eliminated G19-induced cell growth inhibition in U-87 MG cells ( Figure 7C ). Meanwhile, cell cycle arrested in S phase induced by G19 could be thoroughly rescued by NAC in U-87 MG cells ( Figure 7D and E). Additionally, Annexin V/PI analysis demonstrated that pretreatment with NAC also completely blocked G19-induced apoptosis in U-87 MG cells, which was consistent with the cell viability assay results ( Figure 7F and G). All above results suggested that G19 induced cell cycle arrest and apoptotic cell death via promoting intercellular ROS generation in U-87 MG cells.
G19 inhibits U-87 MG cells xenogaft growth in nude mice
Given its encouragement of in vitro activity, we next examined the anti-tumor effect of G19 in vivo. U-87 MG cells were subcutaneously inoculated into the right flank of female nude mice. Different doses of G19 (0.2, 1, 5 and 25 mg/kg) in normal saline were injected via tail vein every other day. After nude mice were administrated with G19 for 26 days, the relative tumor cell growth values T/C (%) at 0.2, 1, 5 and 25 mg/kg of G19 were 79.67, 60.07, 72.98 and 41.89%, respectively. The results showed that G19 could significantly inhibit the growth of U-87 MG cells xenograft in nude mice ( Figure 8A ). During this experiment, the body weight of the mice was not significantly changed in all groups ( Figure 8B ).
G19 alters the expressions of some proteins in U-87 MG cells xenograft in nude mice
Since we showed that G19 inhibited the growth of U-87 MG cells xenograft in nude mice, the next question was whether the important signal effectors changed in vitro was also altered in vivo. To address this, five important proteins in EGFR/Akt/p21 induced cell cycle arrest and ROS/DNA damage induced cell apoptosis signaling pathway, p21, cyclin A, phospho-Akt (Ser 473), phospho-histone H2A.X (Ser 139) and cleaved caspase-3, were chosen to be measured in xenografted tumor tissue after administration of G19. Immunohistochemical analysis was performed to detect the expressions of these proteins in the tumor tissues. Semi-quantitative image analysis on the immunohistochemical section was employed to measure the integrated optical density (IOD) using Image Pro Plus software (Media Cybernetics, Silver Spring, MD). The expressions of p21 ( Figure 8C ), phospho-histone H2A.X (Ser 139) ( Figure 8F ) and cleaved caspase-3 ( Figure 8G ) were dramatically upregulated in the tumor tissue from 25 mg/kg G19-treated group whereas the expressions of cyclin A ( Figure 8D ) and phospho-Akt (Ser 473) ( Figure 8E ) was markedly downregulated compared with control group. Taken together, the results obtained from U-87 MG cells xenografted mice were consistent with that of in vitro experiment in response to G19 treatment.
Discussion
Up to now, the effect of oligosaccharide from G. filicina on tumor cells growth was unclear. Herein, we first reported that G19, one purified sulfated oligosaccharide isolated from G. filicina, could dramatically inhibit U-87 MG human glioma cells growth in vitro and in vivo. We further provided the possible mechanism of the action, as shown in Scheme 1. This anti-proliferate activity might be attributed to (i) G19 bound to EGF and inhibited EGFR phosphorylation to block PI3K/Akt signaling pathway to promote p21 translocation from cytoplasm to nucleus. Then p21 inactivated cyclin A and caused cell cycle arrest; (ii) G19 also induced oxidative stress associated with increased ROS levels and subsequently caused DNA damage. Then DNA damage induced ATM phosphorylation and further activated Chk2/p53 signaling cascade to activate p21. Meanwhile, both intrinsic mitochondria pathway and extrinsic death receptor pathway were triggered to induce cell apoptosis (Scheme 1). In this study, we provided evidence that the generation of mitochondrial ROS and DNA damage induced by G19, as typical phospho-H2A.X foci and "comet" DNA fragments, were detected in the cells (Figure 4 and 5). Elevated ROS levels have been widely accepted as a causative trigger for DNA damage. Further experiment revealed that the phosphorylation RT-PCR analysis using specific gene primers for Bax, Bcl-2, Apaf-1, caspase-9, caspase-3, Fas, FasL and caspase-8. Cells were treated with 0.1 mg/mL G19 for 24 h. 18S RNAwas used as an internal control. Quantification of each band was normalized to 18S RNA. (G and H) Western blot analysis using antibody specific against caspase-3, cleaved caspase-3, PARP, Bcl-2, cytosolic cytochrome c and FasL. Cells were treated with different concentrations of G19 for 24 h. β-actin was used as a control for protein loading. All experiments were repeated thrice. Results are mean ± SD from three independent experiments. (*P < 0.05; **P < 0.01; ***P < 0.001.)
of Chk2 at Thr 68 was remarkably increased in U-87 MG cells ( Figure 4E ). The phosphorylation of Chk2 at Thr 68 is an ATM kinase-characterized event, and no other kinase has been shown to phosphorylate this site. Chk2 phosphorylation is a marker for ATM pathway activation following DNA damage (Matsuoka et al. 1998 ). In accordance with previous reports, phosphorylation of ATM at Ser 1981 was also upregulated upon G19 treatment ( Figure 4E ). Furthermore, Chk2 phosphorylation initiates a cell cycle arrest at an intra-S phase or G2-M transition (Koczor et al. 2009 ). It was consistent with the effects induced by G19 ( Figure 1B and C) .
The tumor suppressor p53 turned out to be an essential downstream mediator and integrator between ATM and growth arrest in G19-treated tumor cells. We demonstrated here that the phosphorylation sites of p53 at Ser 15, Ser 20 and Ser 46 were activated by G19 (Figure 2A ). These evidences suggested that G19 played a positive role on p53 activation. Stabilization and activation of p53 may induce the transcription of many target genes whose protein products either arrest cell growth or initiate apoptosis (Crook et al. 1994; Vogelstein et al. 2000) . PI3K/Akt signaling could modulate the localization of two p53 targets-MDM2 and p21. For MDM2, Akt-mediated phosphorylation of MDM2 at Ser 166 and Ser 168 increases its interaction with p300, allowing MDM2-mediated ubiquitination and degradation of p53 (Grossman et al. 1998; Mayo and Donner 2001; ). Chk2 directly phosphorylates p53 at Ser 20. This effect could interfere with MDM2 binding (Hirao et al. 2000) . In our experiments, G19 could upregulate the expression of total p53 following the downregulated MDM2 expression, similar to the effect of PI3K inhibitor LY294002 on the expression of MDM2 and p53 (Supplementary data, Figure S2 ). The phosphorylation of Akt promotes translocation of MDM2 from the cytoplasm to the nucleus (Mayo and Donner 2001) . The inhibition of MDM2 phosphorylation at Ser 166 ( Figure 2D ) might be due to the downregulation of Akt phosphorylation ( Figure 3A ) during G19 treatment. Clearly, further experiments would be necessary to fully understand this point. For p21, one of the prime transcriptional targets of p53, mediates p53-dependent cell growth and senescence. Contrary to MDM2, the activation of Akt increases the distribution of p21 in the cytoplasm . Indeed, p53 activated by G19 could up-regulate the expression of p21 ( Figure 2B ). The expression of p21 in the nucleus was also upregulated compared with control group (Figure 1F) . Besides, G19 induced senescence in U-87 MG cells at lower concentration (data not shown). Consistent with previous report (Heiss et al. 2007 ), the potential trigger for senescence induced by G19 could be attributed to the increased ROS production as well as activation of DNA damage checkpoint kinase ATM and p21.
In this study, we showed that G19 inhibited PI3K activity and suppressed the phosphorylation of Akt ( Figure 3A and B). Thus, it was concluded that the PI3K/Akt pathway was blocked upon G19 treatment. As we found, G19 could strongly bind to PI3K (Supplementary data, Figure S3 ) whereas the activity of PI3K at cell level was influenced by G19 but not at kinase level ( Figure 3B and C). That might be the result of two possible events. The first was that G19 might internalize into cells and bind to PI3K to affect the function of PI3K at cell level and subsequently influence the phosphorylation of Akt expression. The second was that G19 inhibited the upstream effectors of PI3K/ Akt pathway and suppressed the activity of PI3K at cell level. For the first possible explanation, it was not very clear for us to understand where to bind on the nonactive domain of PI3K by G19 once G19 entered into the cells. However, it is worthy to be further investigated. For the second possible explanation, many members of phospho-RTK, the upstream effectors of PI3K/Akt pathway, were downregulated after the cells were incubated with 0.1 mg/mL G19 for 15 min (data not shown). Among these downregulated phospho-RTKs, we focussed on the phosphorylation of EGFR ( Figure 3D ) that is frequently overexpressed in primary glioblastoma (Furnari et al. 2007 ). Unexpectedly, G19 could not bind to EGFR (data not shown). Instead, it bound to EGF, the ligand for EGFR ( Figure 3F ). The phosphorylation of EGFR was not completely suppressed by 0.1 mg/mL G19 ( Figure 3H ). We speculate that this probably reflects the higher affinity of EGF for EGFR than G19. Thus, we deduced that G19 might disturb the interaction between EGF and EGFR and in turn contribute, at least in part, to the blockade of EGFR/PI3K/Akt pathway. The issues of what the exact structural binding domain of EGF with G19 was and how G19 influenced the interaction between EGF and EGFR needed to be further investigated. Once DNA damage is triggered, cells begin to initiate a cell cycle arrest that would provide a feedback to repair this damage. Hyperactived PI3K/Akt pathway could promote DNA repair in glioblastoma cells (Kao et al. 2007) . EGFR is considered to not only modulate cell proliferation, differentiation as well as apoptosis but also participate in the process of DNA repair (Kriegs et al. 2010; Liccardi et al. 2011) .
In this study, we demonstrated that G19 would play a remarkable interfering role in DNA repair process. It will be interesting to study the effect of G19 on the process of DNA repair. Scheme 1. Proposed mechanism of cell cycle arrest and apoptosis induction by blockage of EGF/EGFR/PI3K/Akt pathway and activation of ATM/Chk2/p53/ p21 pathway in response to G19 treatment in U-87 MG cells. G19 could bind with EGF and then block EGFR/PI3K/Akt pathway. The decrement of phospho-Akt could promote nuclear translocation of p21. The downregulated MDM2 could stabilize p53. Meanwhile, G19 treatment stimulated elevation of ROS levels to induce oxidative DNA damage that mediated by sensor protein ATM. Upon activation, ATM phosphorylated Chk2 and/or also directly activated p53. The stablized and activated p53, which subsequently upregulated target genes such as p21. Then p53/p21 downregulated cyclin A and caused cell cycle arrest. The activated p53 also could trigger both intrinsic mitochondria pathway and extrinsic death receptor pathway to induce cell apoptosis. EGF could partially reduce the ROS generation induced by G19 in U-87 MG cells.
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After the cell cycle is arrested and the damage to DNA continues to intensify, cells would initiate apoptosis. p53 plays an important role in this process. Pifithrin-α could inverse the growth inhibitory effect induced by G19 in U-87 MG cells to some extent ( Figure 4F ). It suggested that cell growth inhibited by G19 was mediated by p53 activation. Both intrinsic mitochondrial pathway and extrinsic death receptor pathway were triggered in tumor cell apoptosis induced by G19 (Figure 6 ). These results were in agreement with previous studies that point out ROS as secondary messenger in apoptosis provoked by anticancer agents, such as resveratrol and acidic polysaccharides form Chinese wolfberry fruits (Juan et al. 2008; He et al. 2012) . Pretreatment with free radical scavenger NAC could completely block G19-induced apoptosis ( Figure 7F and G). We inferred that both apoptotic pathways were associated with ROS accumulation in U-87 MG cells after G19 treatment.
Since tumor cells have increased ROS generation and are under elevated intrinsic oxidative stress, it is conceivable that the tumor cells would be more dependent on antioxidants for cell survival. The mechanisms of redox adaptation include multiple pathways to activate redox-sensitive transcription factors, such as nuclear factor-κB (NF-κB), Nrf2, c-jun and HIF-1. A decrease in redox-sensitive transcription factors activity compromises the cellular ability to eliminate superoxide radicals, and induces ROS generation (Trachootham et al. 2009 ). A luciferase assay could be used to evaluate the transcriptional activity of NF-κB (Fang et al. 2012) . We observed that G19 significantly inhibited NF-κB transcriptional activation stimulated by lipopolysaccharide in a dose-dependent manner (data not published). Thus, we inferred that G19 might induce ROS accumulation through inhibiting NF-κB activation to suppress the expression of antioxidant molecules. A biologic link between NF-κB and EGFR has been suggested by the demonstration that high level of EGFR expression is essential for EGFR-mediated NF-κB activation (Habib et al. 2001; Hirota et al. 2001) . In our work, we found that a tyrosin kinase inhibitor lapatinib could induce ROS accumulation in U-87 MG cells (Supplementary data, Figure S4C and D). In addition, EGF could partially reduce the ROS generation caused by G19 in U-87 MG cells ( Figure 5H and I). It could be inferred that a decreased activation of EGFR might inhibit NF-κB transcriptional activation and suppress the expression of antioxidant molecules to promote ROS generation in U-87 MG cells in response to G19 treatment.
In summary, the results of this study indicate that G19, one purified sulfated oligosaccharide isolated from G. filicina, inhibited cell proliferation of U-87 MG human glioma cells in vitro and in vivo at nontoxic concentration. G19 elicited redox and replication stress that both merged into p53/p21-dependent growth arrest and apoptosis via activation of ATM/Chk2 signaling in U-87 MG cells. The linkage between G19 and endogenous ROS generation shown in this study provided a new insight of molecular mechanism in anticancer research. Moreover, another interesting and significant discovery in this study was that G19 bound to EGF, inhibited the phosphorylation of EGFR. Subsequently, PI3K/Akt signaling was blocked to induce and trigger p21 nuclear translocation and impair cyclin A function after G19 treatment. Further investigation of the likely involvement of G19-mediated EGFR phosphorylation downregulation in EGFR/PI3K/Akt signaling pathway would shed light on the significance in DNA damage induced by G19 in human glioblastoma treatment.
Materials and methods
Chemicals and reagents
Oligosaccharide G19, prepared from G. filicina, was structurally elucidated by infrared radiation (IR), nuclear magnetic resonance (NMR), mass spectrometer (MS) spectra and its purity determined by several conventional methods (highperformance liquid chromatography (HPLC) and thin-layer chromatography (TLC)). It was dissolved in normal saline for experimental use after passing through a 0.22-μm filter. Dulbecco's Modified Eagle's medium (DMEM) was purchased from HyClone (Logan, UT). fetal bovine serum (FBS) was from Gibco BRL (Gaithersburg, MD). PI, MTT and β-actin were from Sigma (St. Louis, MO). The antibody against cyclin A used for immunohistochemistry was from Abcam (San Francisco, CA). Other antibodies against p21, cyclin A, Akt, phospho-Akt (Ser 473), phospho-histone H2A.X (Ser 139), phospho-CDK2 (Thr 160), CDK2, phospho-EGFR (Tyr 1068), phospho-MDM2 (Ser 166), phospho-p53 (Ser 15), phospho-p53 (Ser 20), phospho-p53 (Ser 46), p53, Bcl-2, cytochrome C, FasL, caspase-3, cleaved caspase-3, PARP and histone H3 were purchased from Cell Signaling Technology (Danvers, MA). TRIZOL reagent, penicillin and streptomycin were purchased from Invitrogen (Carlsbad, CA). Pifithrin-α was obtained from Beyotime (Haimen, China). siRNA of p21 were purchased from GenePharma (Shanghai, China). Other reagents were obtained from Sinopharm Chemical Reagent Co., Ltd (Shanghai, China).
Cell line and cell culture U-87 MG human glioma cells were obtained from the Cell Bank in the Type Culture Collection Center in Chinese Academy of Sciences, Shanghai, China. Cells were cultured at 37°C in a 5% CO 2 humidified incubator and maintained in DMEM culture medium supplemented with 10% heatinactivated FBS and antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin).
MTT assay
Cells (4 × 10 3 cells/well) were seeded into the 96-well plate overnight. After treatment, 5 mg/mL MTT was then added to each well and incubated for 4 h. The formazan crystals formed from MTT by the living cells were dissolved in 150 μL dimethyl sulfoxide (DMSO), and then detected by a spectrophotometer (Thermo Scientific, West Palm Beach, FL) at an absorption wavelength of 490 nm. The survival ratio was calculated as (sample/control) × 100%.
Cell cycle and apoptosis analysis Cells (3 × 10 5 cells/well) were plated into a 6-well plate and allowed to attach overnight. After treatment, cells were harvested using 0.25% trypsin, washed with cold phosphate buffer solution (PBS) and fixed in ice-cold 75% ethanol at 4°C overnight. After washing, the cells were incubated with 100 μg/mL G19 inhibits U-87 MG human glioma cells growth in vitro and in vivo RNase A in 37°C water bath for 1 h, and stained with 50 μg/ mL PI at ice box in the dark for 15 min. The DNA content was analyzed by flow cytometry with Cell Quest and Modfit LT 3.0 software (Becton Dickinson, Franklin Lakes, NJ). Apoptotic or necrotic cells were identified by dual-staining with Alexa® Flour 488 Annexin V and PI (Invitrogen, USA). The experiment was carried out according to the manufacturer's instructions. Then cells were analyzed on a flow cytometer with Cell Quest software (Becton Dickinson).
Reverse transcription-polymerase chain reaction Total RNA was extracted from the control and treated group using the TRIZOL reagent according to the manufacturer's instruction. First-strand cDNA was synthesized from 1 μg total RNA using AMV reverse transcriptase (Takara Biotechnology, China). PCR amplification was performed with Ex Taq (Takara Biotechnology, China) using the following conditions: denaturation at 94°C for 30 s, annealing at annealing temperature (T a ) for 30 s and elongation at 72°C for 45 s. The thermal cycling was 30 cycles for caspase-3, caspase-8, caspase-9, Bax, Bcl-2, Apaf-1, Fas and p21, 35 cycles for FasL, 33 cycles for p53, and 25 cycles for 18S RNA. The primers and T a for caspase-3, caspase-8, caspase-9, Bax, Bcl-2, Apaf-1, Fas, FasL and 18S RNA were the same as that used by Zhang et al. (2009) while for p53 was performed as previously described (Gu et al. 2008) . The primers for p21 were 5′-TGTCACTGTCTTGTACCCTTG-3′ (forward) and 5′-ACACAAACTGAGACTAAGGCAG-3′ (reverse). T a was 62°C for p21. RT-PCR products were analyzed and visualized on 2.0% agarose gel containing ethidium bromide (EB). Images were acquired by Tanon 3500 digital gel imaging system (Tanon Science & Technology, China).
Cytoplasmic and nuclear protein extraction
The separation of nuclear and cytoplasmic protein was prepared using Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, China). After treatment, the cells were processed according to manufacture's instructions. All subcellular fractions were stored at −80°C before using for western blotting.
Western blotting analysis
Total cellular protein was isolated by lysing cells with an equal volume of RIPA buffer (Beyotime, China). Protein concentration was determined by BCA protein assay (Beyotime, China). The protein was separated by SDS-PAGE and transferred onto a nitrocellulose membrane (Millipore, MA). The membrane was blocked at room temperature for 30 min, and incubated with primary antibody at 4°C overnight. Protein bands were detected by incubation with horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h, and visualized with chemiluminescence reagent (Pierce, IL).
Gene knockdown using siRNA Two sequences for p21 siRNA were 5′-CUUCGACUUUGU CACCGAG-3′ and 5′-GAUGGAACUUCGACUUUGU-3′. U-87 MG cells (2 × 10 5 cells/well) were seeded into a 6-well plate for 24 h before transfection. siRNA was transfected into cells using Lipofectamine 2000 agent (Invitrogen, CA) according to the instructions from the company.
Determination of PI3K activity
The activity of PI3K at cell level could be measured based on the amount of NADH by GENMED PI3K Assay Kit (Genmed Scientifics, USA). After treatment, the cells were harvested and processed according to manufacture's instructions. Protein concentration was determined by BCA protein assay (Beyotime, China). The negative control and samples were detected at an absorption wavelength of 340 nm at 0 and 5 min using a spectrophotometer (Thermo Scientific). The amount of NADH (μmol/min/mg) was calculated. PI3K activity at kinase level was measured using Kinase-Glo Luminescent Kinase Assay kit from Promega (Madison, WI). Different concentrations of G19 were mixed with kinase buffer in a 384-well plate for 10 min on a shaker. Then kinase substrate (25 μM adenosine triphosphate (ATP) and 50 μM PIP2) was added and incubated with PI3K. Reaction was performed at room temperature for 1 h. An equal volume of Kinase-Glo reagent was then added to stop and stabilize the luminescent signal. The amount of ATP remaining in solution after kinase reaction was measured with a luminometer (Thermo Scientific).
Phospho-RTK analysis
Proteome Profiler™ Human Phospho-RTK Array Kit purchased from R&D Systems (Minneapolis, MN) was employed to assess the expression of phospho-RTKs in U-87 MG cells. After U-87 MG cells were treated with G19 for 15 min, the cells were harvested and processed according to the manufacture's instruction. Chemiluminescence reagent (Pierce) was used for the detection.
QCM analysis
To measure G19-protein interaction, biosensor experiment was carried out on Attana A100 QCM instrument (Attana AB, Sweden). Briefly, 1,3-diaminopropane (DAP) was added to reaction buffer (DMSO/HCOOH, 4:1) containing 10 mg/mL G19 followed by incubation in water bath at 60°C for 2 h. The DAP-G19 solution was collected by using solid phase extraction (SPE) column. After evaporated to dryness, it was dissolved in deionized water and lyophilized. 10 mM Sulfo-NHS-LC-Biotin was incubated with DAP-G19 in PBS at room temperature for 1 h. The biotinylated G19 was purified from nonreactive biotin reagent using SPE column. The Attana biotin sensor surface was mounted in QCM system and equilibrated with running buffer (PBS containing 0.005% Tween-20). Subsequently, streptavidin solution (100 μg/mL) was injected. Next, the biotinylated G19 was immobilized on the streptavidin surface to produce a G19 biosensor surface. The interaction between G19 and protein was measured by injecting protein onto the G19 biosensor surface. A continuous flow of running buffer was at a flow rate of 25 μL/min. The frequency response produced from the interaction was monitored by frequency logging with Attester 1.1 (Attana AB), where the mass change from the bound and released ligand was recorded as the resulting frequency shift.
Measurement of ROS
The change in intracellular ROS was determined by measuring the oxidative conversion of cell permeable DCFH-DA to fluorescent dichlorofluorescein (DCF) using Reactive Oxygen Species Assay Kit (Beyotime, China). After treatment, the cells were divided into two parts. For the first part, cells were incubated with DCFH-DA at 37°C for 30 min. Then they were washed with serum-free medium. The image was captured using fluorescence microscope (Olympus, Japan). For the second part, the cells were harvested and resuspended in serum-free DMEM containing DCFH-DA at 37°C for 30 min. After washing, the cells were subjected to flow cytometry analysis (Becton Dickinson). H 2 O 2 assay H 2 O 2 was detected by Hydrogen Peroxide Assay Kit (Beyotime, China). After treatment, the cells were lysed by schizolysis solution, and then centrifuged at 12,000 × g at 4°C for 5 min. All the operations were carried out on ice. The supernatants and test solution were incubated at room temperature for 30 min and measured instantly with a spectrometer (Thermo Scientific) at a wavelength of 560 nm. The amount of H 2 O 2 was calculated according to standard concentration curve originated from standard solutions upon the identical experiment.
Determination of MMP
MMP was analyzed by employing the Mitochondrial Membrane Potential Assay Kit with JC-1 (Beyotime, China) that accumulated in the mitochondria and emitted fluorescence in a potential sensitive manner. After treatment, the cells were harvested and incubated with JC-1 in a cell incubator for 20 min. We calculated MMP as a ratio between red-and greenpositive cells for the indicated periods of time using a fluorospectrophotometer (Perkin Elmer, Akron, OH).
Comet assay
After treatment, the cells were harvested and resuspended in ice-cold PBS. The cells were mixed with 0.6% (w/v) molten low melting agarose (Sigma) at 37°C at a ratio of 1:4 (v/v). The agarose-cell mixture was placed on a slide precoated with 0.6% (w/v) normal agarose. After solidified at 4°C, the slide was lysed in prechilled lysis solution (2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM Tris-HCl ( pH 10), 10% (v/v) DMSO, 1% (v/v) Triton X-100, and 1% (w/v) sodium sarcosinate) at 4°C in the dark for 3 h. After denaturation in a freshly prepared electrophoresis buffer (300 mM NaOH, 1 mM Na 2 EDTA, pH 13) for 20 min, the slide was subsequently electrophoresed at 300 mA for 20 min. Then, it was immersed in neutralization buffer (400 mM Tris-HCl, pH 7.5), dehydrated, air-dried and stained with EB for 20 min. The slide was visualized by a fluorescence microscope (Olympus, Japan). DNA damage was quantified in at least 50 randomly selected comets per slide as tail moment variable calculated using CometScore™ software.
Immnofluorescent staining
After treatment, the cells were fixed in 4% (w/v) paraformaldehyde at room temperature for 15 min and permeabilized by 0.3% (v/v) Triton. Then, they were blocked with 5% (w/v) bovine serum albumin for 1 h and stained overnight in primary anti-phospho-histone H2A.X (Ser 139). After washing, the cells were incubated with anti-rabbit secondary antibody conjugated with Alexa Fluor® 555 conjugate (Cell Signaling Technology, Danvers, MA) and counterstained with DAPI (Sigma). The morphology of cells were observed and captured by a laser scanning confocal microscope (Olympus, Japan).
Detection of cytoplasmic cytochrome c
The isolation of mitochondria and cytoplasm was performed using Cell Mitochondria Isolation Kit (Beyotime, China). After treatment, the cells were harvested and processed according to the manufacture's instruction. The cytoplasm lysate was subjected to western blot analysis using specific antibody against cytochrome c.
Tumor xenograft growth assay All mice were housed in sterile cages within laminar air flow hoods under specific pathogen-free conditions with sterile food and water ad libitum. All animal experiments were performed according to a protocol approved by the Institutional Animal Care and Use Committee. U-87 MG cells (1.0 × 10 7 /mL resuspended in PBS) were subcutaneously injected into the right flank of female nude mice (six mice/group). After the tumor volume grew to 20 100 mm 3 , different doses of G19 (0.2, 1, 5 and 25 mg/kg) in normal saline and normal saline (vehicle) were injected via tail vein every other day. Tumor volume was measured using a caliber on the indicated days. The tumor volume (V) was calculated as follows formula: V = (length × width 2 )/2. The individual relative tumor volume (RTV) was calculated as follows: RTV = V t /V 0 , where V t was the volume on each day and V 0 was the volume at the beginning of the treatment. The therapeutic effect of the compound was expressed as the volume ratio of treatment to control (T/C). T/C (%) = 100% × (mean RTV of the treated group/mean RTV of the control group). Mice were sacrificed after treatment for 26 days, the tumor tissues were excised, fixed in 4% (w/v) neutral paraformaldehyde and embedded in paraffin for further histological analysis.
Immunohistochemistry
Paraffin-embedded tumor tissues of six mice were sliced into sections for immunohistochemistry staining as previously described (Qiu et al. 2010) . The tissue sections were probed with primary antibody against p21 (1:50), cyclin A (1:200), phospho-Akt (Ser 473) (1:50), phospho-histone H2A.X (Ser 139) (1:400) or cleaved caspase-3 (1:100) at 4°C overnight. After application of the anti-rabbit/mouse secondary antibody and appropriate washes, the signals were detected by staining the sections with 3,3′-diaminobenzidine and counterstaining with hematoxylin. To evaluate the protein expression, semiquantitative image analysis on the immunohistochemical section was employed to measure the IOD using Image Pro Plus software (Media Cybernetics, Silver Spring, MD).
Statistical analysis
Data and statistics were analyzed using GraphPad Prism version 5 software. All graphical data were presented as mean ± SD. Significant difference between the groups was determined using the unpaired Student's t test. A value of P < 0.05 was accepted as an indication of statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001). All the figures shown in this article were obtained from at least three independent experiments with a similar pattern.
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